Welcome to a breakfast seminar with Jan M. Lundberg, President of Lilly Research Laboratories
Alzheimer’s disease (AD) is a health crisis for patients, families and society. Emerging disease modifying AD therapies build on deep understanding of disease pathophysiology of amyloid and tau pathways.
Clinical trials in AD are facilitated by innovative brain imaging technology, but need to catch diagnosed patients at the right stage for the right length of time with the appropriate endpoints. Potentially disease modifying therapeutics in AD are now in late stage clinical trials including both small molecules and biologicals.
Current healthcare system for AD is designed for the symptomatic treatment paradigm and needs to change to reach the patients that will benefit most from new disease modifying therapies.
The breakfast seminar is organized by IVAs division for Biotechnology.